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Human primary endothelial 
label-free biochip assay reveals 
unpredicted functions of plasma 
serine proteases
Márta Lídia Debreczeni1,4, Inna Szekacs  2,4, Boglarka Kovacs2, Andras Saftics2, 
Sándor Kurunczi2, Péter Gál3, József Dobó3, László cervenak1,4* & Robert Horvath  1,4*
Tissue-on-a-chip technologies are more and more important in the investigation of cellular function 
and in the development of novel drugs by allowing the direct screening of substances on human cells. 
Constituting the inner lining of vessel walls, endothelial cells are the key players in various physiological 
processes, moreover, they are the first to be exposed to most drugs currently used. However, to date, 
there is still no appropriate technology for the label-free, real-time and high-throughput monitoring 
of endothelial function. To this end, we developed an optical biosensor-based endothelial label-free 
biochip (EnLaB) assay that meets all the above requirements. Using our EnLaB platform, we screened a 
set of plasma serine proteases as possible endothelial cell activators, and first identified the endothelial 
cell activating function of three important serine proteases – namely kallikrein, C1r and mannan-binding 
lectin-associated serine-protease 2 (MASP-2) – and verified these results in well-established functional 
assays. EnLaB proved to be an effective tool for revealing novel cellular mechanisms as well as for the 
high-throughput screening of various compounds on endothelial cells.
There is an ever-increasing demand to develop reliable biological model systems to study cellular function or to 
test the effect of drug candidates and other bioactive compounds. Modern technology opened up the possibility 
to deposit living cells or even reliable tissue models directly on a transducer surface to monitor their behavior 
in a miniaturized, fast and cost-effective manner. These lab-on-a-chip systems are more and more popular in 
applied biotechnology and their application in basic cell biological research is on the rise1. Moreover, such robust 
and portable devices with primary cells or patient tissues lay the foundation for point-of-care testing in medical 
diagnostics2.
The cells in our body are highly complex machines, which are required to react immediately and adequately 
to the molecules of their environment in order to maintain homeostasis. Although there are several conventional 
methods suitable for studying cell behavior, these are often low-throughput and time-consuming assays, and 
usually rely on the detection of labeled molecules, which can per se affect cellular functions, as they may activate 
unforeseen signaling pathways.
To overcome this problem, the introduction of non-invasive label-free technologies is necessary. Real-time 
and high-throughput biosensor technologies as the basis of new-generation cell-based screening techniques pro-
vide analytical information by the recognition of biological events employing a physical transducer. Resonant 
waveguide grating (RWG) based optical biosensor technologies utilize an evanescent electromagnetic field to 
in situ monitor refractive index changes close to the surface of the sensor in 96- or 384-well microplates. The 
detection is typically limited to a probing depth of ~150 nm due to the exponentially decaying electromagnetic 
evanescent field of the sensing waveguide mode3,4. The technology is commercially available and was successfully 
employed previously to monitor the kinetics of cell–surface and cell membrane receptor–ligand interactions3,5–7, 
binding affinity8, cellular signaling9,10, cytotoxicity11, nanoparticles12 and the functional state of surface-adhered 
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cells down to the single cell level13. The output of the sensor is an integrated signal of dynamic mass redistribution 
(DMR) taking place in the sensing depth above the bottom of each well14. The Epic BT platform is particularly 
suitable for the primary screening of the cellular effects of yet uninvestigated substances, as almost any changes 
in cellular function can affect the refractive index monitored at the bottom surface of the adhered living cells. 
Therefore, valuable information about nanometer-scale cellular and molecular changes can be easily obtained in 
real-time and completely label-free manner providing an outstanding possibility far from being fully explored in 
basic and applied cell-biological researches.
As constituents of the inner lining of all vessel walls, endothelial cells (ECs) are among the first to come into 
contact with the components of the blood. Numerous important physiological processes are regulated by ECs, for 
example, vascular permeability, which is controlled by the alteration of the tightness of inter-endothelial adhesion 
junctions15. As ECs are present everywhere in the body in great numbers and are affected by the pathomechanism 
of several diseases (e.g. atherosclerosis, edematous diseases, sepsis, cancers, etc.), it is particularly important to 
understand how activated blood components and intravenously administered pharmacological agents affect EC 
behavior.
Among blood components, enzymes (mostly serine proteases) of hemostasis and the innate immune response 
are indispensable for maintaining the integrity of the body. Blood serine proteases constitute a very complex 
and highly interconnected network, which – although only for didactic reasons – is divided into three main cas-
cades, namely the coagulation/fibrinolytic, the kinin-kallikrein, and the complement systems. Coagulation and 
fibrinolysis are two extremely interlocking processes that are required to ensure the integrity of blood vessels by 
the occlusion and reparation of injured vessels while keeping the vast majority of blood plasma in a fluid state. The 
kinin-kallikrein system is the main source of the proinflammatory mediator bradykinin, a small molecule with 
diverse physiological roles. The complement system is the most important humoral arm of innate immunity that 
can effectively recognize and eliminate most pathogens immediately after entering bodily fluids16. Some plasma 
serine proteases – for example thrombin and mannan-binding lectin-associated serine protease-1 (MASP-1) of 
the coagulation and complement cascades, respectively – are known to directly affect EC behavior by the cleavage 
of cell surface protease activated receptors (PARs)17, but most plasma serine proteases have not yet been tested 
on ECs.
Human umbilical vein endothelial cell (HUVEC) culture is a widely accepted in vitro model of the inner ves-
sel walls. Gelatin coating is mainly used to assist HUVECs adherence, however, its application on the biosensor 
surface should be carefully considered. The challenge is to create a film of gelatin on the biosensor surface thin 
enough to sense cellular DMR in the exponentially decaying evanescent optical field, while still providing an ideal 
and robust matrix for EC attachment and growth. The thickness and stability of gelatin were characterized using 
quartz crystal microbalance (QCM), optical waveguide lightmode spectroscopy (OWLS), atomic force micros-
copy (AFM) and RWG techniques.
OWLS is a powerful waveguide-based biosensor technique that enables the simultaneous determination of the 
surface mass, refractive index, thickness and internal ordering of self-assembling thin films18–22. Note, the deter-
mined optical thickness is usually underestimated in case of heavily hydrated layers19,22. While OWLS measures 
the mass of polymer chains only (“dry” mass), the mechanical biosensor QCM is sensitive both to the polymer 
chains and to the associated solvent molecules, and measures the so-called cumulative “wet” or hydrated mass as 
well as the corresponding hydrated thickness23. Importantly, the combination of OWLS and QCM data enables to 
determine the mass of bound water and the hydration degree of hydrogel-based coatings22,24. In addition, QCM 
is also sensitive to the rigidity of the formed layer and quantitative viscoelastic data, such as viscosity and shear 
elastic modulus, can also be obtained22,25–27.
For the screening of plasma serine proteases on ECs, we first demonstrate a label-free, high-throughput and 
easy-to-use tissue on a chip system, which is perfectly suitable for studying complex cell behavior on an optimized 
surface coating. In our work, the recently developed resonant waveguide grating based technology was combined 
with human primary endothelial cell layers in an elegant way (endothelial label-free biochip (EnLaB), see Fig. 1). 
Using EnLaB, we are the first to describe a novel function of plasma serine proteases, i.e. MASP-2, kallikrein and 
C1r were able to activate the ECs, which function was validated in various traditional assays.
Results
Biosensor surface modification: optimization of gelatin coatings for cell seeding. Since in vitro 
culturing of HUVECs requires an appropriate surface, initial experiments were conducted to optimize the sensor 
surface coating protocol to achieve reproducible and stable measurement conditions. However, being primary 
cells, HUVECs are not as easily accessible, therefore “more valuable” than immortalized cell lines, such as HeLa 
cells, which are also adherent, but much less vulnerable cells. For this practical reason, HeLa cells were used in 
these initial, surface optimization experiments.
Figure 2 presents the scheme of the measurement principle of QCM-I and OWLS as well the curves of the 
graphs of the raw data. The results on the formation of gelatin coatings obtained by in situ QCM-I and OWLS 
as well as AFM measurements are summarized in Fig. 3. While the QCM-I measurement relies on a generated 
standing acoustic plane wave, OWLS employs the evanescent wave that is generated by the excited waveguide 
modes. The primary data are the resonant frequency as well as the coupling angle corresponding to the excited 
acoustic overtones and waveguide modes, respectively (Fig. 2a,b). From these data, normalized resonant fre-
quency shift (Δfn/n) and dissipation shift (ΔDn) values as well as effective refractive index values (NTE, NTM) are 
subsequently calculated (Fig. 2c,d)22.
The combined analysis of QCM-I and OWLS data revealed the hydration and viscoelastic properties of the 
gelatin coating. Based on the OWLS and QCM-I mass data evaluation, it was found that the hydration degree 
of the layer prepared using the 5 mg/ml solution is 90% as shown in Fig. 3a (hydration degree is defind by the 
surface mass of bound water relative to the hydrated mass). When the 0.2 mg/ml solution was used, the hydrated 
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thickness of the gelatin layer was 9.8 nm, which increased to 16.1 nm when the 5 mg/ml solution was subsequently 
employed (see Fig. 3b). The obtained shear viscosity (η) and shear elastic modulus (μ) data (Fig. 3c) are in good 
agreement with literature values measured for hydrogel-type agarose layers (according to the publication of Dutta 
et al., η = 2.7 mPa·s and μ = 0.21 MPa were obtained for agarose gels)28.
The AFM images showed a homogeneous gelatin coating with both gelatin concentrations on the surface, 
which were very smooth with typical RMS values of 0.2–0.4 nm on a standard 1×1 µm surface, ideal for optical 
biosensor measurements. Note, however, that more particles were observed on the 5 mg/ml coated samples. The 
particles are presumably formed from the gelatin by aggregation, the size of which ranged from 20 nm to 200 nm 
for the 5 mg/ml samples and which were generally smaller for the 0.2 mg/ml samples (Fig. 3d,e).
The coating procedure was finally tested with Epic BT biosensor plates. After recording the baseline signal, the 
gelatin coating was performed at 37 °C, outside the Epic BT instrument. Then, the biosensor plate was placed back 
to the instrument to assess the magnitude and stability of the coating signal. The wavelength shift with 0.2 mg/
ml gelatin showed stable signal in two cases, when the washing step was applied (Fig. 4a, black line), and when 
the gelatin solution was replaced with PBS (Fig. 4a, red line). In contrast, when the gelatin solution remained in 
the well (Fig. 4a,b, blue line), a concentration-dependent drift was observed. A slight drift was also observed in 
Figure 1. Schematic overview of the proposed EnLaB measurement setup. Upper part: cell preparation steps 
(primary cell isolation, culturing, transferring onto the sensor chip surface). The incoupled waveguide mode 
intensity profile is shown in green color. The exponentially decaying evanescent field of the mode senses the 
adhering cells. The waveguide mode is excited by illuminating the grating structure from below using a broad 
range of wavelengths. The resonant wavelength excites the waveguide mode which – after propagating a short 
distance inside the waveguide – couples out into the direction of the substrate (shown in green). The lower part 
illustrates the steps of the biosensor measurements and typically obtained biosensor responses (the detected 
shifts in the resonant wavelength): coating of the chip with gelatin, following with cell attachment to the gelatin 
surface, and subsequent cell treatment by the studied molecular compounds (screening). Illustration of the 
biological effect of the treatment is highlighted in dashed boxes.
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the case of the 5 mg/ml solution, when it was only replaced with PBS (Fig. 4b, red line). These data show that the 
critical step of coating the surface with gelatin is the removing of its excess from the surface. It is noteworthy that 
the higher concentration of gelatin resulted in a larger biosensor signal indicating the formation of a thicker layer. 
HeLa cells showed adhesive properties on both surfaces, however, greater biosensor signal was obtained on cell 
adhesion to gelatin at 0.2 mg/ml (see Fig. 4c,d).
Taken together, the application of 0.2 mg/ml gelatin solution resulted in a more homogenous and thinner layer 
allowing the deposition of larger cell masses inside the evanescent field. Due to these favorable characteristics, we 
employed a 0.2 mg/ml gelatin coating in all of the further experiments with HUVECs.
The Epic BT-based EnLaB system is an optimal platform for the label-free investigation of 
complex EC responses to plasma serine protease treatment. The Epic BT seemed to be an ideal 
candidate platform for the label-free investigation of complex EC behavior. We have successfully created stable, 
confluent endothelial monolayers on the 0.2 mg/ml gelatin coated biosensor surface of 384-well plates. Adding 
Figure 2. Measurement principle of the QCM-I and OWLS biosensor techniques and obtained raw data 
from in situ measurements on gelatin layer formation. (a,b) Raw data obtained from QCM-I and OWLS the 
measurements: the resonance peak around the 3rd overtone resonance frequency (a QCM-I) as well as the 
intensity peaks of the excited modes at the coupling angles (b OWLS). In the case of QCM-I, the frequency and 
full width at half maximum (FWHM) value of the resonance peak are registered at each measurement time and 
the resulting normalized frequency shift (Δfn/n) and dissipation shift (ΔDn) data (the latter calculated from 
FWHM) at the selected n overtones are used for the model fit. (c) Gelatin deposition experiment monitored 
by in situ QCM-I. The measured Δfn/n and ΔDn data are represented by solid lines with different colors, while 
the data resulting from fitting the Voigt-based viscoelastic model are represented by colored dashed lines. 
The graph header and dashed vertical lines indicate the phases of the deposition experiment (P: PBS flow, G1: 
flow of 0.2 mg/ml gelatin solution, G2: flow of 2 mg/ml gelatin solution). (d) Effective refractive index data 
corresponding to the transverse electric (NTE, red line) and magnetic modes (NTM, brown line) obtained by 
parallel OWLS measurement on gelatin layer formation (the experiment was performed with the same phases 
detailed above for QCM-I).
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growth medium to EC monolayers did not induce any changes in the wavelength shift curve (Fig. 5a). On the con-
trary, the total detachment of ECs from the surface in response to trypsin treatment resulted in a great negative 
wavelength shift of −1400 pm (Fig. 5b). However, thrombin – a serine protease known to trigger the contraction 
of ECs and formation of paracellular gaps, thereby reversibly increasing endothelial permeability – induced a 
more moderate, but still definite negative wavelength shift (Fig. 5c). The effect of thrombin was further investi-
gated in 6 different concentrations in the range of 12.5 nM up to 400 nM, and was found to be dose-dependent 
(p < 0.001, ANOVA, post test for linear trend, Fig. 5d). According to these results, EnLaB appeared to be suitable 
for testing the effects of plasma serine proteases on ECs.
New hits identified using EnLaB – plasma serine proteases kallikrein, C1r and MASP-2 induced 
characteristic wavelength shift curves. After fine-tuning the system, we screened active plasma serine 
proteases that have not yet been investigated thoroughly on endothelial monolayers, such as rMASP-2, rMASP-3, 
kallikrein, rC1s, rC1r and FXII. From the tested enzymes, rMASP-3, rC1s, and rFXII did not alter EC behavior, 
but rMASP-2, rC1r and kallikrein treatment resulted in characteristic wavelength shift curves significantly dif-
ferent from the medium control (Fig. 6). Proteases rMASP-2 and kallikrein both induced a negative wavelength 
shift, while rC1r had an opposite effect, resulting in a positive signal. The effect was dose-dependent in all three 
cases.
Figure 3. Results obtained from the combined evaluation of QCM-I and OWLS measurement data, 
supplemented by AFM measurements. (a) Areal mass density of the formed gelatin layer, resulting from QCM-I 
and OWLS measurements. The graph header and dashed vertical lines indicate the phases of the experiment 
(P: PBS flow, G1: flow of 0.2 mg/ml gelatin solution, G2: flow of 2 mg/ml gelatin solution). While the mass curve 
derived from the OWLS measurement (red line) represents the mass of the gelatin chains itself (“dry” mass), 
the mass data obtained from QCM-I represent the mass of the hydrated gelatin layer (“wet” mass). Two types of 
hydrated mass data were calculated: one relying on the Sauerbrey equation (thin green line, calculated from the 
3rd overtone frequency shift data) as well as the other one resulting from the fit of the Voigt-based viscoelastic 
model (thick blue line). The difference between the “wet” and “dry” masses indicates the amount of bound 
water. (b,c) Thickness (b) and viscoelastic properties (c) of the formed gelatin layer (shear viscosity (purple 
line) and shear elastic modulus (red line)), calculated by fitting the Voigt-model. The experimental phases are 
indicated as above in graph (a). The thickness is proportional to the mass data of graph (a) with the factor of 
layer viscosity, estimated to be 1000 kg/m3. (d,e) AFM line scans of gelatin surfaces prepared from 0.2 mg/ml 
(d) and 5 mg/ml (e) gelatin solutions.
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Preincubating rMASP-2 and kallikrein with their natural inhibitor, C1-inhibitor (C1-INH) - which results in 
covalent complex formation - abolished the effects of these proteases. Interestingly, C1-INH was ineffective in the 
case of rC1r, although this protease also forms enzymatically inactive covalent complexes with C1-INH assessed 
by PAGE (data not shown).
Figure 4. Characterization of sensor coatings by the Epic BT. (a,b) Sensor responses after the coating with gelatin 
(a 0.2 mg/ml. b 5 mg/ml). Breaks represent 30 min incubation time outside the instrument. Black: washing two 
times with PBS, Red: replacement of the solution with PBS, Blue: no further treatment. (c) Typical cell adhesion 
curves obtained on gelatin (0.2 mg/ml, 5 mg/ml) coatings after the washing step. At 15 min, 20,000 HeLa cells 
were pipetted into the wells of the sensor plate in 20 μl HEPES HBSS buffer, and recorded for 145 min.
Figure 5. Fine-tuning of the label-free measurement of dynamic mass redistribution on confluent HUVEC 
monolayers. A 384 well biosensor microplate was precoated with 0.2 mg/ml gelatin (37 °C, 20 min, PBS), then 
wells were washed with PBS and confluent monolayers of HUVECs were created on the surface (24 h). The 
microplate was placed into the Epic BT reader, and after the stabilization of the baseline, cell treatments were 
added directly to the culture medium, and the wavelength shift was monitored for 60 min. (a) The culture 
medium was added alone. (b) 2 μM of trypsin was added. (c) 300 nM of thrombin was added. (d) Various 
concentrations of thrombin were added. The response curves were normalized to the medium control and the 
maximum values of the wavelength shift were determined. The figures show representative graphs of at least 3 
independent measurements.
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Validation of the new hits in well-established assays - rMASP-2 and kallikrein triggered intra-
cellular ca2+ mobilization, while all three proteases increased endothelial permeability by the 
disruption of adherent junctions. To validate our results obtained using EnLaB, we first performed an 
intracellular Ca2+ mobilization assay. Treating HUVECs with rMASP-2 and kallikrein induced a Ca2+ response 
similar to thrombin used as positive control. The response was completely blocked by C1-INH in the case of both 
rMASP-2 and kallikrein. On the other hand, rC1r could not elicit a Ca2+ response. rMASP-3 was used to rep-
resent those proteases that did not alter the wavelength shift curve in the Epic BT system, and consistently with 
those results, it failed to trigger a Ca2+ signal (Fig. 7).
Then, we assessed whether rMASP-2, kallikrein or rC1r can affect endothelial permeability, similarly to 
thrombin. According to our results, all three proteases can disrupt EC-EC adhesion by triggering the disappear-
ance of VE-cadherin from the AJs (Fig. 8a), which resulted in a significant permeability increase, 7-fold in the 
case of rMASP-2, 13.4-fold for kallikrein and 6.6-fold for rC1r (Fig. 8b).
In the case of rMASP-2 and kallikrein, the effects could also be blocked by C1-INH. However, – in accord-
ance with the results obtained using the Epic BT system – the rC1r/C1-INH complex induced an even greater 
monolayer permeability (10-fold) than rC1r alone (Fig. 8b). Interestingly, treating HUVECs with rC1r or the 
rC1r/C1-INH complex resulted in the total, homogenous loss of VE-cadherin – in contrast with the other pro-
teases tested, which caused the disappearance of VE-cadherin only in the close proximity of the paracellular gaps 
(Fig. 8a). The plasma derived full-length form of C1r – pC1r – also induced the loss of VE-cadherin, increased 
endothelial permeability and – similarly to rC1r –, it could not be blocked by C1-INH, the pC1r/C1-INH com-
plex induced even stronger responses (data not shown).
Discussion
Here we report the successful development of a new, label-free assay suitable for the real-time monitoring of com-
plex endothelial cell behavior. Using this method, we are the first to describe novel functions – directly related to 
endothelial cell activation – for three important plasma serine proteases.
Figure 6. Effects of plasma serine proteases on the dynamic mass redistribution of confluent endothelial 
monolayers. A 384 well biosensor microplate was precoated with 0.2 mg/ml gelatin (37 °C, 20 min, PBS), then 
the wells were washed with PBS, and confluent monolayers of HUVECs were grown on the surface (24 h). 
The microplate was placed into the Epic BT reader, and after the stabilization of the baseline, serine proteases 
rMASP-3 (1 μM), FXII (2 μM), rC1s (1 μM), rMASP-2 (0.2, 0.6 or 2 μM) and kallikrein (0.2, 0.6 or 2 μM), 
rC1r (0.1, 0.3 or 1 μM) or culture medium alone was added. Proteases rMASP-2, kallikrein and rC1r were also 
applied in complex with their inhibitor, C1-INH (using a three-fold molar excess of C1-INH). Cell treatments 
were added directly to the culture medium, and the wavelength shift was monitored for 60 min. Wavelength 
shift curves were normalized to the medium control. The figures show representative graphs of at least 3 
independent measurements.
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There is an increasing demand for label-free technologies and an expanding number of available experimental 
systems that enable us to monitor cell behavior without the perturbation of cell signaling. Therefore, we aimed to 
develop an assay that takes advantage of these new opportunities. In the newly developed EnLaB assay, we used the 
Figure 7. Effects of plasma serine proteases on intracellular Ca2+ mobilization of HUVECs. Confluent layers 
of HUVECs were seeded onto 96 well microplates and cultured for 24 h. Cells were loaded with 2 μM Fluo-
4-AM for 20 min, then incubated in HBSS for another 20 min. Sequential images were obtained every 5 s by 
fluorescence microscopy. Three photos were taken to determine the baseline fluorescence, then cells were 
treated with thrombin (300 nM), rMASP-3 (1 μM), rMASP-2 (2 μM), rMASP-2/C1-INH complex (2 μM/ 6 μM), 
kallikrein (2 μM), kallikrein/C1-INH complex (2 μM/ 6 μM), rC1r (1 μM), rC1r/C1-INH complex (1 μM/ 3 μM), 
or culture medium alone and the response was monitored for 2 min. Twenty cells per image were analyzed 
using the CellP software (Olympus). (a) Graphs from single, representative experiments. Fluorescence fold 
change values relative to medium control is shown, except in case of Medium control, where all kinetic values 
are normalized to the first fluorescence value. (b) Means of the maximum fluorescence intensity values of 3 
independent experiments, normalized to the control.
9Scientific RepoRtS |         (2020) 10:3303  | https://doi.org/10.1038/s41598-020-60158-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Epic BT platform – a resonant waveguide grating-based technique, which is outstanding among other label-free 
technologies as it combines the possibility of high-throughput screening with the ability of recording complex 
cellular responses coming from both intracellular and extracellular events. Although the impedance-based xCEL-
Ligence system is also capable of the label-free monitoring of cell cultures in a high-throughput screening mode29, 
it is not suitable for the detection of complex cell behavior, as impedance changes result mostly from the changes 
in cell adhesion and not intracellular rearrangements. On the other hand, other label-free techniques – such as 
SPR – are usually incapable of high-throughput screening of cellular effects.
It has to be also emphasized that the optimization of surface coatings in evanescent field-based biosensor 
applications is a crucial step, since the surface coating connects the biological layer (in our case, the endothelial) 
with the optical transducer. Layer thickness, hydration degree and functionality need to be carefully considered. 
In cell-based applications, the layer has to be thin compared to the penetration depth of the evanescent wave, 
but still has to provide full coverage and biological functionality. In the present work, the combined analysis of 
data obtained from parallel optical and mechanical biosensor measurements proved to be an attractive tool to 
determine both the hydration and viscoelastic properties of hydrated nanolayers deposited onto the surface of 
the biochips. Using EnLaB, we investigated confluent EC monolayers on gelatin precoated 384-well microplates 
mounted by optical biosensors. We studied the thickness and roughness of the gelatin-coated surface, which was 
intended to mimic the function of the basal membrane naturally supporting the cells from beneath. A gelatin 
coating applied in a concentration of 0.2 mg/ml was found to be optimal for our purposes. OWLS, QCM and 
AFM measurements showed that this concentration creates a homogenous and highly hydrated layer thin enough 
for the biosensor to “see through”, while demonstrating ideal shear viscosity and shear elastic modulus values 
for the proper mechanical support of ECs. As the confluent HUVEC monolayer is a widely accepted in vitro 
model of the inner vessel wall, we successfully created a homogenous, confluent monolayer of HUVECs on the 
gelatin-coated biosensor surface.
After the fine-tuning of cell culturing, a simple and quick protocol for biosensor experiments was worked 
out using serine proteases – e.g. thrombin and trypsin – that are known to affect EC monolayer properties. As 
Figure 8. Effects of plasma serine proteases on VE-cadherin adhesion junctions and the permeability of 
HUVEC monolayers. (a) Permeability tests were carried out using a modified version of the XPerT technique. 
Briefly, confluent layers of HUVECs were seeded onto biotinylated gelatin-precoated 96-well microplates and 
cultured for 2 days. Cells were treated with thrombin (300 nM), rMASP-3 (1 μM), rMASP-2 (2 μM), rMASP-2/
C1-INH complex (2 μM/ 6 μM), kallikrein (2 μM), kallikrein/C1-INH complex (2 μM/ 6 μM), rC1r (1 μM), 
rC1r/C1-INH complex (1 μM/ 3 μM), or culture medium alone for 20 min. Streptavidin-Alexa488 was added 
to each well for 2 min and cells were fixed with 2% paraformaldehyde-PBS. VE-cadherin adhesion molecules 
were stained with anti-VE-cadherin antibody followed by an Alexa 568-conjugated seconder antibody. Cell 
nuclei were stained using Hoechst 33258. (b) The total area of the streptavidin-Alexa 488 stained paracellular 
gaps was determined on each image using the CellP software. Fold-change data are the mean (+SEM) of three 
independent experiments calculated after normalization to the medium control. **p < 0,001; ***p < 0,0001, 
relative to the control (One-way ANOVA with Tukey post-test).
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our new assay appeared to be an effective method for the label-free screening of various substances on ECs, 
in the current paper we investigated the possible EC-related effects of a subset of plasma serine proteases yet 
underinvestigated on ECs. From the serine proteases tested, MASP-2, C1r and kallikrein induced characteristic 
signals fundamentally different from the untreated control. These proteases were further tested on ECs using 
well-established assays and their EC-related functions were verified.
MASP-2 and C1r are key serine proteases of the complement cascade – the most important humoral arm of 
innate immunity, which provides an immediate response against pathogens entering our blood and other bodily 
fluids.
MASP-2 plays a central role in the lectin pathway of the complement system, which can be activated by the 
sugar motifs of various bacteria and fungi. The importance of MASP-2 is underlined by the fact that in its absence, 
lectin pathway ceases without the formation of the C3 convertase complex30,31, which is a prerequisite for the 
effector functions of the complement system. To date, no direct cellular effects have been described for MASP-2, 
although Asgari et al. showed that MASP-2 is critically important in the pathomechanism of renal ischemia–rep-
erfusion injury independent of its substrate, complement C432. In our new label-free assay, treating HUVECs 
with rMASP-2 resulted in a characteristic response curve. This effect was found to be dose-dependent and could 
be blocked by C1-INH, the natural inhibitor of many plasma serine proteases (also including C1r and kallikrein). 
We further investigated the effects of rMASP-2 on EC monolayers in traditional assays. The results of these tests 
were in accordance with the biosensor experiments; rMASP-2 was able to induce intracellular Ca2+ mobilization 
in HUVECs, which is a classical sign of G-protein coupled receptor (GPCR) mediated EC activation. Moreover, 
rMASP-2 induced a marked disintegration of VE-cadherin – one of the most important adhesion molecules of 
endothelial intercellular adhesion junctions –, and significantly increased endothelial permeability. As all of these 
effects were blocked by the serine protease inhibitor C1-INH, it is plausible that similarly to MASP-117 and throm-
bin33,34, the protease activity of MASP-2 is required for its cellular effects and suggest that the receptor of MASP-2 
is among protease-activated receptors (PARs).
C1r is essential for the initiation of the classical pathway of the complement system, which can be activated by 
IgM or IgG containing immunocomplexes. The absence of C1r is known to contribute to the development of the 
severe autoimmune condition systemic lupus erythematosus (SLE)35, although no direct cellular effects have yet 
been linked to this protease. However, we found that the rC1r treatment of HUVEC monolayers caused a charac-
teristic wavelength shift curve in the Epic BT system. The effect was dose-dependent, but, surprisingly, could not 
be blocked by C1-INH, which is the only known inhibitor of C1r.
Moreover, unlike all the other proteases assessed, rC1r induced a positive wavelength shift in Epic BT system, 
similarly to histamine (data not shown). Although wavelength shift is proportional to the mass redistribution in 
the evanescent field, the exact molecular mechanisms behind the effect is largely unknown. On the other hand, 
rC1r and also the C1-INH/rC1r complex failed to elicit an intracellular Ca2+ mobilization in HUVECs (which 
was the same in the case of pC1r). However, rC1r (and also pC1r) treatment of HUVECs resulted in a dramatic, 
homogenous loss of the adhesion molecule VE-cadherin, which was even more pronounced in the case of C1r/
C1-INH complexes. Consequently, C1r (both recombinant and plasma derived forms) significantly increased 
endothelial permeability, and this response was also greater when ECs were treated with C1r/C1-INH complexes. 
Taken together, these observations suggest that unlike thrombin, MASP-1 or MASP-2, C1r is suspected to affect 
EC monolayer properties independent of its protease activity (as C1-INH could not block the effects of C1r). This 
leads to the assumption that the EC receptor of C1r is not among PARs.
Kallikrein is the central protease of the kinin-kallikrein system and the main contributor to the generation of 
the proinflammatory mediator bradykinin, a small vasoactive peptide with a wide variety of physiological/patho-
logical roles (e.g. edematogenic, vasodilatory, angiogenic and hyperalgesic effect)36,37. The results of Buillet et al. 
suggested that kallikrein is also able to directly increase endothelial permeability independent of bradykinin38. 
The authors linked this effect to the kallikrein-mediated cleavage of VE-cadherin on ECs, but the phenomenon 
was not sufficiently investigated. Consistent with these results, we found that kallikrein may indeed affect EC 
monolayer properties as it caused a characteristic wavelength shift curve. This effect was dose-dependent and 
could be completely blocked by C1-INH. In addition, we showed that kallikrein is able to induce intracellular 
Ca2+ mobilization in HUVECs, suggesting that it can also activate intracellular signal transduction pathways in 
ECs. Moreover, kallikrein treatment caused the disruption of VE-cadherin adhesion junctions of HUVECs and 
significantly increased endothelial permeability. Both effects were blocked by C1-INH. Reconciliation of our 
results and the findings of Buillet et al. suggests that kallikrein has a triple effect on EC monolayers. Besides its 
contribution to the generation of the edematogenic factor bradykinin, kallikrein can directly affect endothelial 
permeability – not only by the cleavage of adhesion molecule VE-cadherin, but also by the activation of ECs, 
which can lead to an active contraction of the cells. As the latter effect of kallikrein was also likely to require its 
protease activity (it was blocked by C1-INH), the EC receptors of kallikrein are also possibly among PARs.
Our findings that plasma serine proteases MASP-2, C1r, and kallikrein can affect EC behavior are of 
high physiological relevance, as these proteases are in direct contact with the endothelium. Due to their 
permeability-increasing effect, there is a possibility that MASP-2, C1r and kallikrein can play a role in the path-
omechanism of life-threatening circulatory conditions – e.g. hereditary angioedema or sepsis – where edema 
formation and activation of plasma protease cascades occur simultaneously.
The challenges we faced during this study outline the directions for further research. One such direction is 
to increase the duration of experiments with EnLab. Although, in this phase of the study we aimed to investigate 
the short-term effects of the proteases (as the signaling of PARs typically manifests in an early cellular response), 
we are planning to develop an incubator compatible arrangement with sample handling, which would allow 
long-term monitoring of cellular monolayers and their responses to external stimuli. Another future plan is to 
develop the method to be able to distinguish between different species in the same sample. It is quite clear from 
the literature as well as from our own experiments that the answer of the cells to the stimulus applied is rather 
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complex. At this point, we envision EnLab primarily as a screening platform to find EC activating factors, but if a 
database of such cellular signals is built up, spectral decomposition might predict the main acting species in the 
sample. An additional exciting question is to investigate the mechanism of action of C1r. The fact that the cellular 
effects of rC1r could not be blocked with C1- inhibitor – which otherwise inhibited its enzymatic activity – sug-
gests that rC1r does not exert its effect through its protease activity, cleaving endothelial PARs. Probably, rC1r 
activates its receptor through a receptor-ligand binding interaction, possibly further stabilized by C1-inhibitor. 
This issue would be rather important to clarify, since no C1r-receptor has been revealed so far.
The most important strength of our method is that it offers a simple and label-free alternative for the 
high-throughput screening of various agents on ECs and other epithelial cells, therefore we plan to broaden the 
spectrum of the molecules and cell types to be investigated with EnLab. Our search for additional EC activating 
plasma proteases will continue as well as we intend to study the effects of several other molecules, even possible 
drug candidates. As we consider the EnLaB assay suitable for studying monolayers of all adherent cell types, we 
also plan to adapt the assay for other endothelial and epithelial cell types. Our goal is to model different tissues, 
where a cell monolayer is exposed to various types of agonists or is especially important in transport processes 
(e.g. models of the intestinal villi, or glomerular epithelial cells).
In conclusion, our newly developed EnLaB assay was found to be suitable for the identification of agents with a 
potential of affecting EC monolayer properties. The advantageous properties of EnLaB makes it an ideal platform 
for both basic research to assess cellular functions of adherent cells and also for pharmaceutics to test libraries of 
drug candidates.
Methods
Reagents. Due to the limited accessibility of high-purity plasma derived forms, we used recombinant cata-
lytic fragments of human MASP-1, MASP-2, MASP-3, C1s and C1r, all of them containing only the CCP1, CCP2 
and SP domains of the proteases (hereinafter referred to as rMASPs, rC1s and rC1r). The recombinant proteases 
were produced in E. coli39 and purified as described earlier40. The preparations were found to be free of bacterial 
contaminations (routinely checked as described earlier). Furthermore, it was shown in our previous study that the 
plasma purified, full-length form of rMASP-1 is functionally equivalent to the recombinant catalytic fragment as 
the two forms elicit the same cellular responses41.
In the case of thrombin, FXII and kallikrein, human plasma derived forms were used, while trypsin was pro-
duced from bovine plasma. Effects of rC1r were validated with human plasma derived C1r (pC1r).
Other reagents were purchased from Sigma-Aldrich, unless stated otherwise.
Preparation and culturing of human umbilical vein endothelial cells (HUVECs). HUVECs were 
isolated by collagenase digestion from fresh umbilical cords obtained during normal deliveries of healthy neo-
nates as described earlier by our group42,43. Cells were cultured in gelatin-precoated flasks (Corning® Costar®) 
in MCDB-131 medium (Life Technologies), completed with 5% heat-inactivated fetal calf serum (FCS), 2 ng/ml 
human recombinant epidermal growth factor (hrEGF, R&D Systems), 1 ng/ml human recombinant basic fibro-
blast growth factor (hrBFGF), 0.3% Insulin Transferrin Selenium (Life Technologies), 1% Chemically Defined 
Lipid Concentrate (Life Technologies), 1% Glutamax (Life Technologies), 1% Penicillin-Streptomycin antibiotics, 
5 μg/ml Ascorbic acid, 250 nM Hydrocortisone, 10 mM HEPES, and 7.5 U/ml Heparin (hereinafter referred to as 
Comp-MCDB). Cells were cultured in 5 mg/ml gelatin precoated cell culture flasks (Corning) until use.
For permeability tests and measurements of intracellular Ca2+ mobilization, a modified version of AIM-V 
medium (Life Technologies) was used, completed with 1% filtrated, heat inactivated bovine serum (PAN 
Biotech), 1 ng/ml hrBFGF growth factor, 2 ng/ml hrEGF (R&D Systems), and 7.5 U/ml Heparin (hereinafter: 
Comp-AIM-V).
HUVECs were used from passages 2 to 4, and each experiment was repeated with cells from two to four differ-
ent individuals. This study was conducted in accordance with the WMA Declaration of Helsinki, and the protocol 
was approved by the Semmelweis University Institutional Review Board (permission number: TUKEB141/2015). 
Written informed consent was provided by all participants prior to inclusion.
HeLa cells culture. HeLa cells (Sigma-Aldrich) were maintained in Dulbecco’s modified Eagle’s medium, 
supplemented with 10% fetal bovine serum (Biowest SAS, France), 4 mM L-glutamine, 100 U/ml penicillin and 
100 µg/ml streptomycin solution. Cells were cultured in a humidified atmosphere containing 5% CO2 at 37 °C. 
On reaching 80% confluence, cells were detached every 3–4 days using 0.05% (w/v) trypsin, 0.02% (w/v) EDTA 
solution.
Optical waveguide lightmode spectroscopy. The sensing principle of OWLS is based on the evanes-
cent waves of the guided waveguide modes18,19,21. For the measurements, a BIOS-1 instrument (MicroVacuum 
Ltd., Hungary) was used with planar optical waveguide, which consists of a SiO2-TiO2 sol-gel waveguide layer 
with grating on a glass substrate (OWLS chip type 2400 μV, MicroVacuum Ltd., Hungary). The grating serves to 
in-couple the He-Ne laser beam (632.8 nm) into the chip, and zeroth-order transverse electric (TE) and trans-
verse magnetic (TM) modes are excited in the waveguide. The chips were equipped in a microfluidic assembly 
mounted with a septum. A peristaltic pump (Ismatec, Reglo) maintained the constant 1 μl/s flow in the liquid 
cell44. The refractive indices of the different solutions (nc) were measured by a refractometer at 632.8 nm (J157 
Automatic refractometer, Rudolph). To evaluate the recorded OWLS data, a 4-layer mode equation was applied45. 
The experiments were carried out at room temperature. The steps of the experiments were the following: stable 
PBS baseline, 20 min 0.2 mg/ml gelatin flow, washing with PBS until stable signal, 20 min 5 mg/ml gelatin flow, 
washing with PBS until stable signal, again 20 min 5 mg/ml gelatin flow, washing with PBS until stable signal.
1 2Scientific RepoRtS |         (2020) 10:3303  | https://doi.org/10.1038/s41598-020-60158-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Quartz crystal microbalance. The QCM technique measures the frequency shift in the resonance of a 
piezoelectric quartz crystal, generated by an added mass on the sensor surface. At the same time, the dissipated 
energy of the oscillation is also recorded, enabling to characterize the viscoelastic behavior of the deposited 
adlayer. The in situ QCM measurements were performed by a QCM-I (QCM with impedance measurement) 
instrument (MicroVacuum Ltd., Hungary) using sensor chips with resonance frequency of 5 MHz22. The gold 
surface of the chips was covered by the same SiO2-TiO2 sol-gel waveguide material that is applied in OWLS. 
The chips were mounted in a microfluidic assembly equipped with a septum. The constant 1 μl/s flow rate was 
maintained by a peristaltic pump. The QCM experiments were carried out in parallel to the OWLS experiments 
in the same environmental conditions and performing the same experimental steps (see the above description for 
the OWLS measurements). The measured fundamental and overtone frequencies were the following: 5, 15, 25, 
25 MHz, corresponding to the overtone numbers of n = 1, 3, 5, 7.
The obtained frequency and dissipation shift data (Δfn, ΔDn) were evaluated and the viscoelastic analysis was 
performed by our developed MATLAB code applying Voinova’s Voigt-based viscoelastic model25.
Atomic force microscopy. AFM was performed with a commercial instrument (Nanosurf FlexAFM, 
Nanosurf, Switzerland). All imaging was performed under liquids (PBS). The images were recorded in dynamic 
mode with a Multi75Gd-G type probe. The recorded images were evaluated by the Gwyddion software.
Epic BT biosensor technique. The Epic BT instrument (Corning Incorporated, Corning, NY, USA) illu-
minates a 96- or 384-well microplate (#5080, #5040, Corning Incorporated, Corning, NY, USA) – mounted by an 
individual RWG-based sensor in each well – and noninvasively monitors refractive index changes in a ~150 nm 
deep evanescent electromagnetic field over the sensor surface. An RWG-based optical biosensor consists of a 
waveguiding layer of Nb2O5 supported by a corrugated glass substrate. The characteristic wavelength, at which 
the waveguide mode and evanescent field is created, is called the resonant wavelength. Cellular responses upon 
stimuli change the local refractive index inside the evanescent field, thus the resonant wavelength shifts to a new 
value and the biosensor signal is recorded kinetically in real time. The instrument scans the wavelength between 
825 and 840 nm in every 3 s each well of the microplate allowing 96 or 384 parallel measurements3,6,46.
Preparation of the Epic biosensor surface with gelatin coatings. For the Epic BT measurement, gel-
atin was applied in two concentrations (0.2 and 5 mg/ml in PBS) to provide a biocompatible surface. The sensor 
surface coatings were created by adding 60 μl of gelatin solutions to the wells of 96-well Epic cell assay microplate 
with further incubation for 30 min at 37 °C. There are several ways to prepare gelatin coating on a solid support. 
Thereafter, to compare the usually applied protocol steps for coating preparations and its subsequent influence 
on layer properties, the following steps were performed in three different ways: i) no further manipulation was 
applied, ii) gelatin solution was aspirated and PBS was added to the wells, iii) wells of the biosensor plate were 
rinsed two times with PBS.
HeLa cell adhesion assay on gelatin-coatings. Upon surface modification by gelatin-coatings and 
Epic BT measurement, all wells were rinsed with 20 mM HEPES HBSS pH 7.4 (assay buffer) three times, and 
baselines were recorded in the wells with 60 μl of assay buffer for 1 h. Meanwhile, HeLa cells were removed from 
tissue culture dishes using a trypsin-EDTA solution. Trypsin digestion was terminated by the addition of com-
pleted medium and the harvested cells were centrifuged at 200 × g for 5 min. The cell pellet was resuspended in 
assay buffer and 20 μl of cell suspension containing 20,000 cells were added to the sensor wells and signals were 
recorded for additional 130 min. All measurements were repeated at room temperature three times.
Label-free measurement of dynamic mass redistribution on confluent endothelial monolayers 
(EnLaB). 384-well biosensor microplates were coated with 0.2 mg/ml gelatin – diluted in PBS – at 37 °C for 
20 min and then wells were washed with PBS2 times. HUVECs were seeded onto the coated surface of biosensor 
microplate and were let attach in a humidified incubator for a confluent monolayer formation for 24 h.
An Epic biosensor plate with adhered cells was let cool down to room temperature for approximately 15 min 
before starting the experiment to prevent condensation, and then was placed into an Epic BT reader. Stable 
baselines had been established for all wells, compounds from the source plate were added to the wells using 
an electronic 16-channel pipette Finnpipette™ Novus (Thermo Fisher Scientific, Waltham, MA, USA) in step-
ping mode. Cells were treated with plasma serine proteases trypsin (2 μM), thrombin (used as a positive control 
in every experiment in 300 nM, Merck-Millipore), FXII (2 μM, Innovative Research), kallikrein (0.2, 0.6 and 
2 μM, Innovative Research), rMASP-2 (0.2, 0.6 and 2 μM), rMASP-3 (1 μM), rC1s (1 μM), rC1r (0.1, 0.3 and 
1 μM), pC1r (1 μM, Merck-Millipore). Proteases rMASP-2, kallikrein and rC1r were also applied in complex with 
human plasma derived C1-INH (Berinert®, CSL Behring, added in 3 times the molar amount of the proteases 
and incubated together for 30 min before cell treatment). Complex formation was checked by polyacrylamide gel 
electrophoresis. Protease solutions were directly added to the growth medium and wavelength shift changes were 
monitored for 60 min after cell treatment. Wavelength shift curves were normalized by subtracting the values of 
the medium control (negative control). All treatments were repeated within each experiment at room tempera-
ture three times, and experiments were repeated using ECs from different individuals.
Permeability measurements and visualization of VE-cadherin adhesion molecules. We used a 
modified version of the recently developed XPerT technique47 for permeability measurements. Briefly, confluent 
layers of HUVECs were seeded onto 96 well plates precoated with 0.25 mg/ml biotinylated gelatin and cultured 
in Comp-AIM-V for 2 days. Following cell treatment, Streptavidin-Alexa488 (2 µg/ml, Life Technologies) was 
added to each well for 2 min. After cell fixation (1% paraformaldehyde-PBS) 2 pictures were taken of each well 
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with an Olympus IX-81 fluorescence microscope mounted by an Olympus XM-10 camera. To determine the size 
of the stained area, quantitative image analysis was carried out on each image using the CellP software (Olympus). 
Thrombin (300 nM) was used as a positive control in every experiment.
To allow covalent complex formation, human plasma derived C1-INH (the natural inhibitor of MASP-2 and 
C1r) was preincubated with the proteases in a 3-fold molar excess for 30 min before treating HUVECs.
Adhesion molecule VE-cadherin was stained with anti-VE-cadherin (Santa Cruz) antibody, followed by 
Alexa568 labeled goat-anti-rabbit secondary antibody. Nuclei of the cells were labeled with Hoechst 33258 
(200 ng/ml, Molecular Probes).
intracellular ca2+ mobilization assay. Mobilization of intracellular Ca2+was measured as described 
by our group earlier48. Briefly, confluent layers of HUVECs were seeded onto 96 well plates and cultured in 
Comp-AIM-V for 1 day. Cells were loaded with 2 µM Fluo-4-AM (Molecular Probes) for 20 min, then incu-
bated in HBSS for another 20 min. Sequential images were obtained every 5 seconds by fluorescence microscopy. 
Baseline fluorescence was determined from the first three images, then cells were treated with the serine proteases 
or complexes of these proteases with C1-INH (added in 3-fold molar excess) and incubated together for 30 min 
before the treatment of the cells). The response was recorded for 2 min. Fluorescence intensity change of twenty 
cells was analyzed on each image with the CellP software.
Statistical analysis. All experiments were performed in triplicates and repeated using HUVECs from 
at least two different individuals. The statistical analysis was carried out using GraphPad Prism version 5.01 
(GraphPad software, La Jolla, California, USA). To determine statistical significance of the results, one-way 
ANOVA with Tukey post test was conducted, where a p value of ≤0.05 was considered significant.
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